Absci Sales Fall 54 Percent

Absci reported Q2 2025 GAAP revenue of $0.6 million, significantly missing analyst estimates by 52.3% and marking a steep decline from the prior year, while a 34% surge in R&D spending led to a wider net loss of $0.24 per share. Despite these financial challenges, the biotechnology company highlighted pipeline advancements, including ABS-101 entering Phase 1 trials, and expanded strategic collaborations with partners like Almirall and AMD. Crucially, a $64 million capital raise in July 2025 has extended Absci's cash runway into the first half of 2028, providing financial flexibility amidst ongoing reliance on milestone achievements and partnership success.

Analysis

Absci's second-quarter fiscal 2025 results present a clear dichotomy between deteriorating near-term financials and progress on long-term strategic objectives. The company reported GAAP revenue of just $0.6 million, a significant 52.3% miss against analyst estimates and a 53.8% decline year-over-year, highlighting the unpredictable nature of milestone-based revenue. This shortfall, coupled with a deliberate 34% increase in research and development spending to $20.5 million, drove the GAAP net loss to widen to $30.6 million, or $0.24 per share. However, this increased cash burn is directly funding key pipeline assets, including the ABS-101 program which entered a Phase 1 trial and has interim data expected in the second half of 2025. The most critical development was a post-quarter $64 million capital raise, which management affirms extends the company's financial runway into the first half of 2028. This infusion provides substantial insulation from immediate financing pressures, allowing the company to focus on executing its clinical and partnership strategy, which includes an expanded collaboration with Almirall potentially worth up to $650 million in future payments.

Key Decisions for Investors

• Investors should look beyond the significant Q2 revenue miss and widening loss, as the key takeaway is the company's extended cash runway into H1 2028, which de-risks the medium-term funding profile and provides a long window for pipeline maturation.
• The primary catalysts to monitor are clinical milestones, specifically the interim Phase 1 data for the ABS-101 program expected in H2 2025, and the signing of new, substantive partnership agreements that would validate the AI platform and provide non-dilutive capital.
• Given the pre-revenue stage, high R&D burn, and binary risk of clinical trials, positions in ABSI should be considered high-risk and long-term, with an investment thesis predicated on the success of its drug discovery platform rather than current financial metrics.